HeartRhythm

SEPTEMBER 4, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

Heart BMJ

FEBRUARY 12, 2024

Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). Introduction Management of heart failure (HF) requires multidisciplinary, pharmacological and non-pharmacological strategies, one component of which is exercise training.

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40

Open Heart

APRIL 24, 2024

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. We aimed to determine the clinical characteristics which were associated with optimisation of HF pharmacological intervention in the clinic, conducting multivariate regression analysis.

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Circulation: Heart Failure

JANUARY 26, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pharmacology Obesity Circulation 40

European Journal of Heart Failure

JANUARY 21, 2024

Abstract Despite remarkable improvements in the management of heart failure (HF), HF remains one of the most rapidly growing cardiovascular condition resulting in a substantial burden on healthcare systems worldwide. Therefore, non-pharmacological interventions targeting autonomic imbalance in HF have been evaluated.

Heart Failure 40

Heart Failure Pharmacology Physiology Article 40

European Journal of Heart Failure

NOVEMBER 14, 2023

In the QUEST trial, QLQX reduced the combined risk of cardiovascular death or heart failure hospitalization (hazard ratio 0.78, 95% confidence interval 0.68–0.90), Taken collectively, these observations support a conceptual framework for understanding the mechanism of action for QLQX in heart failure.

Heart Failure 40

Heart Failure Pharmacology Hospital Article 40

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF).

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. However, cost-effectiveness considerations should be made.

Heart Failure 40

Heart Failure Pharmacology Innovation Outcomes 40

The British Journal of Cardiology

MAY 13, 2024

There is no excerpt because this is a protected post.

Heart Failure 52

Heart Failure Pharmacology 52

European Journal of Heart Failure

OCTOBER 17, 2023

Associations of colchicine-related plasma proteins, incident heart failure (HF) and cardiac structure and function. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Circulation Pharmacology 40

Journal of Cardiovascular Pharmacology

DECEMBER 20, 2023

Background: Midodrine is occasionally used off-label to treat hypotension associated with advanced heart failure. Objectives: We sought to evaluate the effect of midodrine upon the GDMT prescription pattern and clinical outcomes of patients with decompensated systolic heart failure.

Heart Failure 52

Heart Failure Hospital Outcomes Article 52

Journal of Cardiovascular Pharmacology

MAY 2, 2024

This review summarizes the multiple roles of miRNAs in the prediction and treatment of heart failure (HF), including the molecular mechanisms regulating cell apoptosis, myocardial fibrosis, cardiac hypertrophy and ventricular remodelling, and highlights the importance of miRNAs in the prognosis of HF.

Heart Failure 40

Heart Failure Research Article 40

Journal of Cardiovascular Pharmacology

AUGUST 6, 2024

Patients undergoing anthracycline-based cancer treatments have an increased risk of heart failure (HF) and adverse metabolic outcomes such as malnutrition and cachexia. Patients undergoing anthracycline-based cancer treatments have an increased risk of heart failure (HF) and adverse metabolic outcomes such as malnutrition and cachexia.

Heart Failure 40

Heart Failure Cancer Research Outcomes 40

Journal of the American Heart Association

FEBRUARY 23, 2024

Journal of the American Heart Association, Ahead of Print. BackgroundThe effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied.

Cardiogenic Shock 40

Cardiogenic Shock Heart Failure Pharmacology Hospital 40

Journal of Cardiovascular Pharmacology

AUGUST 6, 2024

Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload. Guidelines recommend intravenous (IV) loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload.

Heart Failure 40

Heart Failure Hospital Article 40

Circulation

NOVEMBER 14, 2023

BACKGROUND:Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics. Circulation, Ahead of Print. Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism.

Heart Failure 40

Heart Failure Pharmacology Cardiac Function Circulation 40

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Pharmacology Diabetes 40

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Heart failure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide. Heart failure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide.

Heart Failure 40

Heart Failure Biomarkers Article 40

Frontiers in Cardiovascular Medicine

JULY 24, 2024

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

Pulmonary 52

Pulmonary Hypertension Angioplasty Pharmacology 52

The British Journal of Cardiology

AUGUST 21, 2024

In this historical review, we explore its journey from ancient wisdom to becoming a cornerstone of heart failure (HF) therapy, including discovery of its pharmacological properties and an appraisal of early clinical studies.

Atrial Fibrillation 52

Atrial Fibrillation Pharmacology Heart Failure 52

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heart failure, hypertension, and numerous cardiomyopathies. Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heart failure, hypertension, and numerous cardiomyopathies.

Heart Failure 40

Heart Failure Cardiomyopathy Laboratory Cardiovascular Disease 40

Frontiers in Cardiovascular Medicine

FEBRUARY 4, 2024

Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heart failure.

Pharmacology 69

Pharmacology Obesity Heart Failure Diabetes 69

Heart BMJ

MAY 10, 2024

Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

Arrhythmia 40

Arrhythmia Myocardial Infarction Atrial Fibrillation Heart Failure 40

Journal of Cardiovascular Pharmacology

MARCH 4, 2024

Diastolic dysfunction (DD) in heart failure (HF) is associated with increased myocardial cytosolic calcium, and calcium-efflux via the sodium-calcium-exchanger depends on the sodium gradient. Beta-3-adrenoceptor (β3-AR) agonists lower cytosolic sodium and have reversed organ congestion. NCT01876433.

Heart Failure 40

Heart Failure Biomarkers Heart Disease Article 40

Heart BMJ

JUNE 25, 2024

The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.

Cardiovascular Disease 59

Cardiovascular Disease Myocardial Infarction Pharmacology Angina 59

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

levosimendan treatment in the management of advanced heart failure. levosimendan treatment in the management of advanced heart failure. In the latest years several studies described the impact of repetitive/intermittent i.v In the latest years several studies described the impact of repetitive/intermittent i.v

Heart Failure 40

Heart Failure Article 40

Journal of Cardiovascular Pharmacology

NOVEMBER 16, 2023

ABSTRACT: Management of heart failure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms. Management of heart failure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms.

Heart Failure 40

Heart Failure ICU Hospital Article 40

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Dementia 45

DAIC

MAY 14, 2024

In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.

Cardiomyopathy 126

Cardiomyopathy Exercise Chest Pain Quality of Life 126

Journal of Cardiovascular Pharmacology

NOVEMBER 14, 2023

Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF).

Heart Failure 40

Heart Failure Outcomes Hospital Diabetes 40

HeartRhythm

OCTOBER 15, 2023

Ivabradine is an anti-arrhythmic agent that reduces the heart rate through inhibition of the pacemaker current of the sinoatrial node. It has been used to treat both inappropriate sinus tachycardia and sinus tachycardia related to heart failure in children and adults.

Congenital Heart Disease 40

Congenital Heart Disease Tachycardia Congenital Heart Disease 40

Cardiometabolic Health Congress

AUGUST 30, 2024

Pharmacological Interventions : Use of antihypertensive medications, lipid-lowering agents, and antidiabetic drugs. Coronary Heart Disease : Initiate beta-blockers in patients with acute MI and normal LVEF unless contraindicated or if they have heart failure.

Cardiac Rehabilitation 52

Cardiac Rehabilitation Heart Failure Quality of Life Aortic 52

Journal of Cardiovascular Pharmacology

APRIL 23, 2024

An abstract is unavailable. This article is available as a PDF only.

Heart Failure 40

Heart Failure Article 40

DAIC

APRIL 3, 2024

The “Pharmacology Program” will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients. 24 is guided by prominent clinicians and leaders, and focuses on important fundamentals in managing and treating heart conditions.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Journal of Cardiovascular Pharmacology

APRIL 1, 2024

No abstract available

Heart Failure 40

Heart Failure 40

European Journal of Heart Failure

DECEMBER 22, 2023

gradient ≥30 mmHg at rest or ≥50 mmHg after Valsalva maneuver or exercise) despite pharmacological or non-pharmacological therapy. Results Pharmacological or non-pharmacological therapy resolved LVOTO in 1,044 (61.2%) of the 1,706 HOCM patients under active follow-up, whereas 662 patients (38.8%) had persistent LVOTO.

Cardiomyopathy 40

Cardiomyopathy Pharmacology Atrial Fibrillation Outpatient 40

ADN Center of Excellence

SEPTEMBER 2, 2024

AFib is associated with a fivefold increased risk of stroke, and it is also linked to heart failure, chronic fatigue, and other serious health issues. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59